![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Chidamide (Epidaza®) , an oral subtype-selective HDAC inhibitor, combined with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), has been officially approved by the NMPA for treatment of DLBCL with positive MYC and BCL2 expression.
Lead Product(s): Chidamide,Rituximab,Cyclophosphamide
Therapeutic Area: Oncology Product Name: Epidaza
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2024
Details:
Bilessglu (chiglitazar sodium) is a novel peroxisome proliferator activation-related receptor pan-agonist, which is being evaluated for the treatment of non-alcoholic steatohepatitis.
Lead Product(s): Chiglitazar Sodium
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Bilessglu
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2024
Details:
NWY001 is world's first PD-1/CD40 bispecific antibody. It is currently being evaluated in phase 1 clinical trials for the treatment of patients with advanced solid tumors.
Lead Product(s): NWY001
Therapeutic Area: Oncology Product Name: NWY001
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
CS32582 is a novel small molecule and highly selective allosteric inhibitor of Tyrosine Kinase 2 (TYK2). It got approval for conducting clinical trials for the treatment of psoriasis.
Lead Product(s): CS32582
Therapeutic Area: Dermatology Product Name: CS32582
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2023
Details:
Data from the registration study of HBI-8000 has demonstrated clinically meaningful responses despite the advanced stage of disease and acceptable safety profile to address an important unmet medical need in this patient population.
Lead Product(s): Chidamide
Therapeutic Area: Oncology Product Name: HBI-8000
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: HUYA Bioscience International
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2021
Details:
Chiauranib is an innovative, 3-pathway targeted kinase small molecule inhibitor with high selectivity against Auroa B /VEGFRs/CSF1R currently entering Phase III clinical trials in China.
Lead Product(s): Chiauranib
Therapeutic Area: Oncology Product Name: CS2164
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2021
Details:
CS12192 showed significant efficacy in multiple autoimmune disease models in preclinical studies.
Lead Product(s): CS12192
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2020